Skip Navigation


A first-line PDE-5 inhibitor that can help improve exercise ability

ADCIRCA® (tadalafil) is a phosphodiesterase 5 inhibitor (PDE-5i) indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).
For US Healthcare Professionals Only

Privacy Policy

This Privacy Policy describes what information we may collect about you; how we use your information; how we protect it; and what choices you have. Health is a very personal, private subject, and we want you to feel as comfortable as possible visiting our various Web sites and using their respective services. This Privacy Policy applies only to websites that directly link to this policy when you click on Privacy Policy in the website footer.

Personally Identifiable Information

United Therapeutics Corporation ("UT") may collect personally identifiable information such as name, address, telephone number, e‐mail address, or other information only when voluntarily submitted by the visitor (i.e. on a web form you fill out and submit). UT uses or discloses personally identified information only with the visitor's consent. UT will comply with any limitations on use communicated when personally identifiable information is collected.

UT will not sell, trade, or rent your personally identifiable information to others. UT may however, share your personally identifiable information with other UT businesses or affiliates, our agents, contractors or business partners in order that they may perform services for us.

UT may use your personally identifiable information for the purposes of sending you information about this website, marketing communications about its products, information about disease states treated with UT’s products, information about support groups for patients and peer givers, educational opportunities, conferences, and seminars, and similar information.

Non‐Personally Identifiable Information

UT collects non‐personally identifiable information in aggregate form to track data such as the total number of visits to our web sites, the number of visitors to each page of our web sites, and the domain names of our visitors' Internet service providers. We use this information, which remains in aggregate form, to understand how our visitors use our web sites so that we may make them better. We may also share this information with our partners or other outside companies. This information is gathered primarily through the use of "cookies." You may be able to change the manner in which your browser manages cookies through your browser’s privacy settings. NO PERSONALLY IDENTIFIABLE INFORMATION IS OBTAINED IN THIS PROCESS.

UT uses third party advertising companies to advertise on our behalf across the Internet. These third parties may collect anonymous information about your visits to our website, and your interaction with our ads. This is primarily accomplished through technologies including cookies and Action Tags (commonly referred to as a Web Beacons or GIF tags), which are placed on various places within our website. NO PERSONALLY IDENTIFIABLE INFORMATION IS DISCLOSED IN THIS PROCESS.


UT uses technical and organizational security precautions to protect your data from manipulation, loss, destruction or access by unauthorized persons. Any personal data that is provided to UT by you will be secured in transit to prevent its possible misuse by third parties. Our security procedures are revised from time to time based on new technological developments.

Voluntary Disclosures

Any communications or material that you transmit to, or post on, the site by electronic mail or otherwise, including any data, questions, comments, suggestions, or the like, is, and will be treated as, non‐confidential and non‐proprietary information, and UT shall have no obligation of any kind with respect to such information except as otherwise stated in this Privacy Policy.

Links to Other Web Sites

UT web sites may provide links to other web sites as a service to our viewers. These linked web sites are intended to provide helpful information. However, UT does not endorse and is not responsible for the content of third‐party sites. Nor does UT have any control over the information you may choose to provide these sites. This Privacy Policy does not apply to linked sites.

Changes to Privacy Policy

Any changes to this Privacy Policy will be communicated promptly on this page. Please check back periodically.

HOW TO CONTACT United Therapeutics.
If you have questions or comments about this Privacy Statement, please contact:
Office of General Counsel
United Therapeutics/United Therapeutics

Important Safety Information for ADCIRCA® (tadalafil) tablets


  • Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden, unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.
  • Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA


  • Cardiovascular: Patients who experience anginal chest pain after taking ADCIRCA should seek immediate medical attention
  • Hypotension: Phosphodiesterase 5 inhibitors (PDE-5is), including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, carefully consider whether patients with underlying cardiovascular disease could be adversely affected by such actions.
  • Worsening Pulmonary Vascular Occlusive Disease: Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these patients is not recommended
  • Vision/Hearing: Patients who experience a sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), or sudden decrease or loss of hearing after taking ADCIRCA should seek immediate medical attention
  • Prolonged Erection: In rare instances, men taking PDE-5is (including tadalafil) for ED reported an erection lasting more than four hours. Male patients who experience a prolonged erection should seek immediate medical attention


  • Special Populations (Pregnant or Expecting Pregnancy): Limited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.
  • Special Populations (Renal or Hepatic Impairment): The use of ADCIRCA is not recommended for patients with severe renal or hepatic impairment. Please see Full Prescribing Information for dosing recommendations for patients with mild to moderate renal or hepatic impairment
  • Potential Drug Interactions: The use of ADCIRCA with alpha blockers, blood pressure medications, or alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (light-headedness or fainting)
  • Potential Drug Interactions: Tadalafil is metabolized predominately by CYP3A in the liver. Use of ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir. For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with potent inducers of CYP3A, such as rifampin, should be avoided
  • Potential Drug Interactions: ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is used to treat erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). The safety and efficacy of combinations of ADCIRCA with Cialis or other PDE-5is have not been studied. Therefore, the use of such combinations is not recommended


  • Adverse Reactions: The most common adverse event with ADCIRCA is headache (42% ADCIRCA vs 15% placebo). Other common adverse events (reported by ≥9% of patients on ADCIRCA and more frequent than placebo by 2%) include myalgia (14% vs 4%), nasopharyngitis (13% vs 7%), flushing (13% vs 2%), respiratory tract infection (13% vs 6%), extremity pain (11% vs 2%), nausea (11% vs 6%), back pain (10% vs 6%), dyspepsia (10% vs 2%), and nasal congestion (9% vs 1%)


For more information about ADCIRCA, please see the Full Prescribing Information and
Patient Information or call 1-800-545-5979.

-Thomas A Gieseke - 3 illustrations for Adcirca: pillbox with empty "Sunday" compartment, isolated dog and isolated pedometer. Indefinite buyout of rights for use in print and electronic media (iPad presentation) for use by Adcirca only -Copyright Clearance Center - Wolters Kluwer Health, Circulation, Nazzareno Galie, Bruce H. Brundage, Hossein A. Ghofrani, Ronald J. Oudiz, Gerald Simmonneau, Zeenat Safdar, Shelley Shapiro..., Tadalafil Therapy for Pulmonary Arterial Hypertension, License No: 3177700012726 -Nicholais Photography - Unlimited use of photos in print, digital, web for pro and consumer in the US -Bella Agency - Victoria Gardner, unlimited use in print, digital and web